Highlights PD-L1 expression by immunohistochemistry is positive in more than half on stage III non-small lung cancer. PD-L1 expression by immunohistochemistry had no relationship with clinical characteristics. PD-L1 expression by immunohistochemistry is not related to progression-free or overall survival in patients treated with chemoradiotherapy with or without surgery. ABSTRACT Objective: Currently programmed cell death protein 1 (PD-1) inhibitors in combination with other therapies are being evaluated to determine their efficacy in cancer treatment. However, the effect of PD-ligand (L) 1 […]
